Delivers Net Revenue of $86.0 Million, Including Record International Medical Cannabis Net Revenue of $61.4 Million, Representing a 44% Yoy Increase
Generated Adjusted EBITDA1 of $14.0 Million, With Free Cash Flow1
STAMFORD, Conn., Nov. 3, 2026 /CNW/ -- Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today acknowledges the
Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration.
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on
NASDAQ | TSX: ACBRevised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board. Aurora's Special Committee is actively exploring strategic alternatives to
NASDAQ | TSX: ACBMulti-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output.Enhanced facility adopts Aurora's proven cultivation
Aurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete. Shareholders are
NASDAQ | TSX: ACBCuraleaf has yet to file a Notice of Variation and Change to revise its offer. Once filed, the Special Committee will complete a thorough and comprehensive review prior to issuing a formal
NASDAQ | TSX: ACBAurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws.Aurora intends to demonstrate that Curaleaf's Circular has not
NASDAQ| TSX: ACBRe-affirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA1Following the receipt of EU-GMP certification in July, Safari Flower Company is expected to contribute
NASDAQ | TSX: ACBCuraleaf's announcement is a desperate effort to shift attention away from the fundamental issue facing shareholders: its inadequate hostile bid undervalues Aurora.Curaleaf's attempt to
EDMONTON, AB, Sept. 9, 2026 /CNW/ -- Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a biopharmaceutical leader with 25 years of
HighlightsCuraleaf Offers a 45% Premium and Meaningful Future Upside: Aurora shareholders can realize immediate value alongside the opportunity to participate in the upside of a substantially larger, more diversified
NASDAQ | TSX: ACBCuraleaf's hostile and opportunistic bid significantly undervalues Aurora, and aims to capture Aurora's assets at a discountAurora is debt free and holds $149 million in cash1, Curaleaf carries
